[Comparison of the efficacy of cefotaxime alone and the combination cefazolin-tobramycin in the treatment of enterobacterial septicemia].
In a prospective, randomized study we compared cefotaxime (C) with tobramycin plus cefazolin (C + T) in the treatment of Enterobacterial septicemia. Twenty-five patients received C and twenty two C + T. There are 8 treatment failures, in C + T group, 3 in C group. We observed 5 adverse effects, 2 in the C group (1 reversible collapse and 1 Pseudomonas aeruginosa superinfection) and 3 in the C + T group (acute renal failures). We conclude that C may be more effective and less toxic than cefazolin plus tobramycin for patients with Enterobacterial septicemia.
Arich
C
C
Gouby
A
A
Bengler
C
C
Ardilouze
J L
JL
Dubois
A
A
Joubert
P
P
Hansel
S
S
Janbon
C
C
Fabre
S
S
D000368:Aged; D002437:Cefazolin / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D011897:Random Allocation; D018805:Sepsis / Q000188:drug therapy*; D014031:Tobramycin / Q000627:therapeutic use*
D002437:Cefazolin; D002439:Cefotaxime; D014031:Tobramycin
Comparaison de l'efficacité du céfotaxime seul et de l'association céfazoline-tobramycine dans le traitement des septicémies à Entérobactéries.